Samsung Bioepis Announces Approval of Ustekinumab Biosimilar in Japan
Ustekinumab BS Subcutaneous Injection 45mg Syringes 'NIPRO' has been granted marketing approval in Japan First marketing approval under the partnership with NIPRO CORPORATION, paving the way for expanding treatment option for patients in Japan 'NIPRO' will be
(Financial Post, 2025-12-22T23:03:58Z)